Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
EVAXEvaxion(EVAX) GlobeNewswire News Room·2024-10-09 20:00

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform's unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data allows for continuous refinement of AIImmunology™ thereby broadening the commercial po ...